Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Every row

Showing 3 of 382 rows for Tau propagation mechanism (preclinical target rationale). One row per study per exposure: a study that tested two different things appears twice, once for each.

Scroll the table sideways to see every column.

Research and outcomes, 3 rows. Every row links to its source.
Exposure Question Direction Outcome measured Design People Effect size, as the source reported it Source
Tau propagation mechanism (preclinical target rationale) Medicines Treatment No direction reported
why

A mechanism study: it shows Arc packages tau into extracellular vesicles and that cell-to-cell tau transmission is almost absent in Arc knockout mice, with Arc levels correlating with phosphorylated tau in human AD brain vesicles. It tests no intervention and estimates no effect on an outcome.

Tau content and seeding potential of brain extracellular vesicles, and intercellular tau transmission, in tau-transgenic mice lacking Arc None not stated not established — pubmed abstract reports no numeric effect size. Cell 2026
✓ Peer-reviewed PMID 42372723
Tau propagation mechanism (preclinical target rationale) Medicines Treatment Harm
why

Direction is for tau seeding activity: substantial hippocampal and neocortical seeding was present even without overt neocortical tangles and predicted region-specific cognitive performance and longitudinal decline; seeding and modification profiles tracked neuritic plaque density and separated AD from PART.

Tau seeding activity and post-translational modifications in hippocampus and neocortex of Braak-matched AD neuropathologic change versus primary age-related tauopathy, and relation to cognition None 38 not established — pubmed abstract reports no numeric effect size. Nature Communications 2025
✓ Peer-reviewed PMID 39984462
Tau propagation mechanism (preclinical target rationale) Medicines Treatment No direction reported
why

A model-building and screening study: it identifies over 500 genetic modifiers of tau propagation (including VPS29 and the UFMylation cascade) and shows UFMylation inhibition suppresses seeded propagation in vitro and in vivo. It estimates no effect on a clinical outcome.

Seeding-induced tau propagation in human iPSC-derived 4R-P301S neurons, and genetic modifiers found by CRISPRi screen None not stated not established — pubmed abstract reports no numeric effect size. Cell 2024
✓ Peer-reviewed PMID 38582079

How this table was built, and where it is weak →

Last updated